u/elin_varga

Held 7.5 for five months. Everyone kept asking when I was going to 10. The answer was never, because 7.5 was working.

2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.

Small fix — you have described interval stretching and called it a taper. The exposure profiles differ.

Do you have a baseline from before you started?

This. Asking what reference standard was used separates a real analytical claim from a plausible-looking one.

Yes. Naming conventions in this corner are loose enough that the same word covers several different molecules.

Added ApoB to the panel after a thread here. It told me something the standard lipid panel had been hiding.

lab reference ranges are not treatment targets

Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.

What is the waist doing? That is usually the number still moving during a scale stall.

Agreed on assay changes. A lab switching platforms between your draws is invisible unless you ask.

Which country and which plan year are we talking about?

stopping is a plan, not an event

Agreed on the plan-year point. Criteria that applied last year may simply not apply now.

step therapy is a documentation problem, not an argument

Storage conditions came back specific rather than generic when I asked. That told me somebody had actually done stability work.

private plans and provincial plans are different fights entirely

The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.

Health Canada approval is not coverage

Disagree with the framing. Regain is the documented outcome after discontinuation; calling it a personal failure is both wrong and corrosive.

How many weeks between the two measurements?

one measurement is a point, two is a line, three is a trend

Adding the obvious one — take it to whoever ordered the panel. This board cannot read it for you.

hydration status moves a surprising number of markers

appetite comes back before the weight does

Agreed — and the exposure lag means the first fortnight tells you almost nothing.

Employer-sponsored plans have their own criteria and appeal processes, independent of the provincial formulary. Which one applies determines everything about the route.

Push back: approval by the national regulator says nothing about whether any plan will pay.

Agreed. The trend is the signal. A single value is a snapshot of one morning.

net peptide content is where the surprises live

What are you planning to watch for, and over what period?

the appetite effect is blunter than sema, in a good way, most weeks

Correction: that is regulatory approval, not coverage. They are separate decisions by separate bodies.

Not convinced by the attribution. Weight loss alone moves that marker and you have no way to separate the two.

Employer-sponsored plans have their own criteria and appeal processes, independent of the provincial formulary. Which one applies determines everything about the route.

Storage guidance that names a temperature, a state and a duration reflects actual stability work.

Disagreeing with this bit: handling for one compound does not transfer to another by default.

Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.

Different laboratories use different assay platforms with different calibration. Comparing across labs adds a systematic offset that is invisible on the report.